JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Fasciocutaneous flaps.

It is difficult to be objective about the fasciocutaneous system of flaps, whose development continues at an alarming speed. The references cited in this article, by no means comprehensive, are testimony to that. We have tried to be selective in our choice of reference, and anyone familiar with these references will have a good understanding of the fasciocutaneous system. These flaps have been recognized for less than 10 years, but their origins have been well based on an anatomical foundation. The revival in the anatomical basis of flaps, whether they be skin based, muscle based, or fascia based, is, we think, one of the most significant factors in the huge advance we have seen in reconstructive techniques in the last decade. To put reconstructive surgery in perspective, we see it in the following way: 1. Distant origins from ancient Egypt through Tagliacozzi to Dieffenbach. 2. The birth of modern reconstructive surgery, 1900 to 1930. 3. Skin flaps and the age of the tube, 1930 to 1960. 4. Anatomical renaissance; the axial skin flap and microsurgery. 5. The 1970s, decade of the muscle and musculocutaneous flaps. 6. The 1980s, decade of the fasciocutaneous flap. We repeat that to see our present efforts objectively is difficult. What is close to us seems more important, but as we progress further away from the origins of the fasciocutaneous flap, some aspects of these flaps will be seen as more important than others. The concept of including the fascia to produce a composite fascial skin flap is of fundamental importance. The discovery of these flaps is a milestone in reconstructive surgery. Our anatomical understanding of all flaps is also of paramount importance. Some of the individually described fasciocutaneous flaps will always remain best buys; some will be forgotten--and maybe even rediscovered.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app